Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Key Points

• Mirum Pharmaceuticals SVP Jolanda Howe sold 40,000 shares at an average price of $100, generating $4 million. Her remaining stake fell 96.91% to 1,274 shares, following several additional sales since June.
• Mirum’s stock recently traded at $102.24, with a $6.64 billion market capitalization and a 52-week range of $63.23 to $130.00. The company reported quarterly revenue of $176.24 million, up 37.9% year over year, but missed EPS expectations with a loss of $1.06 per share.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $137.33, despite TD Cowen reducing its target to $140.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. This represents a 96.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total value of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM traded up $1.37 during trading hours on Wednesday, reaching $102.24. The stock had a trading volume of 556,260 shares, compared to its average volume of 885,061. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00. The company has a 50 day moving average price of $111.14 and a two-hundred day moving average price of $102.03. The stock has a market capitalization of $6.64 billion, a PE ratio of -7.03 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. During the same quarter in the prior year, the company posted ($0.12) earnings per share. The firm's revenue was up 37.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the subject of a number of recent research reports. TD Cowen dropped their price objective on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Evercore restated an "outperform" rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Citigroup reaffirmed an "outperform" rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research note on Monday, June 15th. Finally, Raymond James Financial reissued a "strong-buy" rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.33.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $32,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Comerica Bank raised its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after purchasing an additional 278 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source